Welcome to our dedicated page for Pressure Bio news (Ticker: PBIO), a resource for investors and traders seeking the latest updates and insights on Pressure Bio stock.
Pressure BioSciences Inc. (PBIO) is a biotechnology innovator specializing in pressure cycling technology (PCT) and UltraShear nanoemulsion platforms. This page provides investors and industry professionals with a comprehensive collection of official announcements, financial disclosures, and scientific developments related to the company's patented methods for enhancing bio-molecular interactions.
Access timely updates on PBIO's advancements in pharmaceutical formulation, nutraceutical delivery systems, and strategic partnerships. Key content includes earnings reports, technology licensing agreements, clinical application progress, and regulatory milestones. All materials are sourced directly from company filings and verified industry channels.
Regularly refreshed content ensures stakeholders maintain current awareness of PBIO's work in creating stable nanoemulsions for improved drug bioavailability. Bookmark this page for efficient tracking of the company's progress in pressure-based biomolecule manipulation techniques and their commercial applications.
Pressure BioSciences, Inc. (PBIO) announced an aggressive growth plan for the second half of 2021 following a strong first half. Key goals include closing an acquisition in the agrochemicals sector, improving the balance sheet by converting debt to equity, launching the UST-based nanoemulsions platform, and completing an up-listing to NASDAQ or NYSE. The company aims for its first million-dollar quarter, with projected revenues of $2.5 million in the second half. Achievements include a solid Q1 and new patent awards, establishing a positive trajectory toward profitability.
Pressure BioSciences (OTCQB: PBIO) has announced the creation of a wholly-owned subsidiary, PBI Agrochem, Inc., and placed an order exceeding $500,000 for eco-friendly agrochemical materials to meet initial demand. The company aims to leverage its Ultra Shear Technology™ for improving the efficacy of agrochemicals, while a major asset acquisition is anticipated soon. With the growing demand for food production, the agrochemical market is projected to reach $131 billion by 2023. PBI is also focused on eliminating debt and considers up-listing to a larger exchange.
Pressure BioSciences, Inc. (OTCQB:PBIO) will present at the Emerging Growth Conference on July 21, 2021, showcasing advancements in its Ultra Shear Technology™ (UST) for CBD and Astaxanthin processing. CEO Richard T. Schumacher will discuss the company's acquisition of assets from a global eco-friendly agrochemicals firm. Key highlights include significant stability improvements of UST-processed CBD oil and the antioxidant benefits of Astaxanthin. These breakthroughs position PBIO for potential market expansion, particularly in the burgeoning CBD market projected to reach $13 billion by 2028.
Pressure BioSciences, Inc. (OTCQB:PBIO) announced groundbreaking results using its Ultra Shear Technology (UST) platform to produce water-soluble nanoemulsions of CBD oil. These nanoemulsions show over one year of stability under various storage conditions, significantly improving CBD absorption and bioavailability. Industry experts have praised the long-term stability and potential of these products, indicating a major advancement in the CBD market, particularly for food, beverage, biotherapeutics, and nutraceuticals. The global CBD market is expected to expand from $2.8B in 2020 to $13B by 2028.
Pressure BioSciences (OTCQB:PBIO) announced a breakthrough in the processing of astaxanthin, a potent antioxidant, using its Ultra Shear Technology (UST). This new method produces nanoemulsions that significantly enhance the absorption of astaxanthin, making it more bioavailable in both oral and topical applications. The company reported stability of these nanoemulsions for at least four months at room temperature, which is crucial for market competitiveness. Pressure BioSciences is targeting the billion-dollar astaxanthin market and is in discussions with potential partners for commercialization.
Pressure BioSciences, Inc. (OTCQB:PBIO) will participate in the Emerging Growth Conference on June 23, 2021, featuring an interactive presentation by CEO Richard T. Schumacher. The company reported a significant revenue growth of 121% in Q1 2021, driven by increased instrument sales (235%) and consumables (81%). The presentation will highlight the anticipated Ultra Shear Technology commercial release in Q4 2021 and plans for acquiring a global eco-friendly agrochemical supplier. The event aims to connect with investors and analysts.
Pressure BioSciences, Inc. (OTCQB: PBIO) will participate in the LD Micro Virtual Invitational Conference XI on June 10, 2021. CEO Richard T. Schumacher will discuss the company's robust revenue growth in 2021, the upcoming launch of its Ultra Shear Technology™ platform, and the acquisition of eco-friendly agrochemical assets. Highlights from Q1 2021 include a 121% increase in total revenue and a 235% rise in instrument sales. Investors can register for the conference here.
Pressure BioSciences reported a significant Q1 2021 revenue increase of 121% to $559,900, driven by instrument sales up 235% and consumables increasing 81%.
Operating losses decreased by 23% to $1,075,100, with a net loss per share improving to $(1.45). The company anticipates continuing growth, with Q2 revenue already surpassing Q2 2020 totals. A definitive agreement for acquiring an eco-friendly agrochemical supplier is underway, and new collaborations are expected to enhance product offerings.
Pressure BioSciences, Inc. (PBIO) reported a significant rebound in its Q1 2021 financial results, marking the strongest quarter since Q4 2018, with revenue surpassing Q2 2020 levels. The company is also nearing the acquisition of an accretive, eco-friendly agrochemical supplier, which aligns with its strategic growth objectives. A teleconference is scheduled for May 19, 2021, to discuss these results and provide further business updates.
Pressure BioSciences, Inc. (PBIO) has been awarded three new patents for its Ultra Shear Technology (UST), enhancing its intellectual property portfolio to 29 patents. These patents were issued in Japan, Australia, and China, focusing on high-quality nanoemulsions beneficial for various industries, including food and pharmaceuticals. The company plans to launch the BaroShear K45 processing system in Q4 2021, shifting to a leasing model for stable revenue. Collaborations with The Ohio State University target liquid food applications, indicating strong market potential for UST.
FAQ
What is the current stock price of Pressure Bio (PBIO)?
What is the market cap of Pressure Bio (PBIO)?
